FDA issued a draft guidance document July 30 intended to establish a quicker mechanism for reviewers to weed out certain deficient device pre-market approval applications, with the aim of focusing the agency’s limited review resources on applications that meet at least bare-minimum requirements for completion and data validity.
The draft guidelines, “Acceptance and Filing Review for Pre-Market Approval Applications,” update FDA’s 2003 PMA filing guidance. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?